A pan-cancer analysis of the oncogenic role of branched-chain aminotransferase 1 (BCAT1) in human tumors

A pan-cancer analysis reveals the multifaceted role of PABPC1L in immune regulation and therapy response

An integrated pan-cancer analysis of PABPC1L expression and function in 33 human malignant tumors identified PABPC1L as exhibiting oncogenic properties and is proposed to function as a key regulator of tumorigenesis and immunotherapy resistance.

Comprehensive Pan-Cancer Analysis Reveals the Prognostic, Molecular, and Immunological Significance of EPS8

Background Epidermal Growth Factor Receptor Pathway Substrate 8 (EPS8) is believed to function as a tumor driver; however, to understand its molecular characteristics across tumors, a comprehensive pan-cancer analysis of EPS8 is lacking. Objective This study aimed to investigate the prognostic, molecular, and immunological significance of EPS8 across multiple human cancers. Methods Comprehensive analyses were conducted using GEPIA2, UALCAN, TIMER2.0, cBioPortal, SMART, GSCA, Enrichr, and the TCGAplot R package to evaluate survival prognosis, gene expression, DNA methylation, immune infiltration, proteomic expression, tumor mutational burden (TMB), microsatellite instability (MSI), genetic alterations, drug sensitivity, and enriched pathways. Results EPS8 overexpression in LGG (p = 7.2 × 10−5) and PAAD (p = 9.4 × 10−6) was significantly associated with poor overall survival and disease-free survival. Amplification was the most common genetic alteration, with alteration frequencies approaching 6% in TGCT and UCEC. In KIRC and PAAD, EPS8 expression correlated with tumor stage. Immune infiltration analysis revealed significant associations between EPS8 expression and immune cells. EPS8 expression also showed significant correlations with both TMB and MSI in STAD and ESCA. Enrichment analysis indicated an association between EPS8 and regulation of the actin cytoskeleton and similar pathways. Conclusion These findings suggest that EPS8 has prognostic and immunological significance across multiple cancer types and may serve as a potential biomarker. The observed associations with immune-related features and drug response provide a basis for future experimental studies to evaluate its role in cancer biology and its potential relevance to immunotherapy.

CDC20B Dysregulation: Links to Tumor Prognosis and Immunity.

OBJECTIVE This study aimed to clarify the pan-cancer expression pattern, upstream regulatory mechanisms, prognostic relevance, and immune associations of CDC20B. METHOD Using public databases (GTEx, GEO, and TCGA), we examined CDC20B expression and its associations with prognosis and tumor immunity across multiple cancers. Immunohistochemistry (IHC) on an independent clinical cohort was performed to validate CDC20B upregulation in tumor tissues. Promoter methylation, genetic alterations, and immune infiltration were analyzed using bioinformatics tools (cBioPortal, UALCAN, TIMER2.0, ESTIMATE). Functional enrichment was assessed by GSEA and single-cell state analysis (CancerSEA). RESULTS CDC20B was markedly upregulated in most tumor types (p < 0.001), with strong diagnostic efficiency (AUC > 0.7 in 15 cancers) and potential regulation by promoter hypomethylation. IHC confirmed its overexpression in clinical tumor tissues. However, the prognostic impact of CDC20B was cancer-type-specific: high expression correlated with poor overall survival in UCS, LGG, KIRC, and OV, but with favorable survival in BRCA, LUAD, and PAAD. CDC20B expression was associated with immune infiltration patterns, showing negative correlations with ImmuneScore in most cancers but positive correlations with CD8+ T cells in PAAD. Functional analyses indicated involvement in EMT, KRAS/NF-κB signaling, and DNA damage response pathways. DISCUSSION The dual prognostic role of CDC20B suggests context-dependent functions, likely influenced by tumor microenvironment composition and underlying oncogenic programs. Promoter hypomethylation emerges as a potential epigenetic driver of overexpression. The associations with immune modulation and genomic instability suggest that CDC20B is a candidate biomarker, though causal relationships require experimental validation. CONCLUSION CDC20B may contribute to tumor progression in a context-dependent manner, with its prognostic impact varying across cancer types. Its role in tumor immunity and oncogenic pathways warrants further investigation, particularly in stratified patient populations.

TPI1 promotes malignant progression and ferroptosis resistance in head and neck squamous cell carcinoma

This study identifies TPI1 as a key tumor-promoting factor and independent prognostic biomarker in HNSCC, providing a promising therapeutic target for overcoming ferroptosis evasion in HNSCC.

Assessing the significance of CCNE1 overexpression in triple negative breast cancer.

Prognostic value of FUBP1 in Colorectal cancer and association with immune microenvironment characteristics.

OBJECTIVE To investigate FUBP1 expression, its prognostic value, impact on the tumor microenvironment (TME), and drug sensitivity in colorectal cancer (CRC), and to explore its potential underlying mechanisms. METHODS Using data from The Cancer Genome Atlas (TCGA), we analyzed FUBP1 expression in CRC, evaluated its prognostic value via survival analysis and nomogram construction, performed pathway enrichment analysis, and assessed immune cell infiltration and Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data (ESTIMATE) scores. We further conducted immunohistochemistry (IHC) validation on an independent institutional cohort and analyzed the Gene Expression Omnibus (GEO) single-cell RNA sequencing dataset GSE132465 (n = 63,689 cells) to examine the association between FUBP1 expression and the tumor immune microenvironment at single-cell resolution. RESULTS FUBP1 was highly expressed in CRC (P < 0.001), particularly in younger patients. High FUBP1 expression was associated with improved overall survival in univariate analysis (HR = 0.68, P = 0.028), yet this association was not maintained as an independent prognostic factor after adjustment for other clinical covariates (HR = 0.722, P = 0.098). Immunohistochemistry results from the independent cohort confirmed upregulated FUBP1 protein in 90% of CRC specimens. Single-cell analysis revealed that FUBP1-high cell clusters exhibited markedly reduced immune cell infiltration (35.97%vs 62.96%, P < 0.001), indicating an immunosuppressive "cold" tumor microenvironment. Tumors with high FUBP1 expression also displayed elevated PD-L1, PD-1, and CTLA4 expression, lower half-maximal inhibitory concentration (IC50) values for oxaliplatin, irinotecan, and 5-fluorouracil, and higher Immune Phenotype Score (IPS) for anti-PD-1 monotherapy or combined anti-CTLA-4 immunotherapy. FUBP1 expression was correlated with increased expression of MYC, TP53, and their downstream target genes (CCND1, CDK4, BAX, CDKN1A). CONCLUSION FUBP1 is highly expressed in CRC and associated with an immunosuppressive "cold" tumor microenvironment characterized by decreased immune cell infiltration, while it correlates with favorable chemotherapeutic sensitivity. FUBP1 may serve as a potential predictive biomarker for responses to chemotherapy and immunotherapy, rather than an independent prognostic indicator for survival. Its linkage to MYC and TP53 signaling pathways warrants further mechanistic investigation.